Zihao Ou

Zihao Ou

Auto-generated profile, based on publicly available information

Zihao Ou

Department of Laboratory Medicine, Nanfang Hospital, Southern Medical University, Guangzhou, China

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 August 2017 in Experimental and Therapeutic Medicine
Verified
Journal Article
Closed access
PDF file
FWFeifan Wu
Feifan Wu
XGXianfeng Guo
Xianfeng Guo
JZJiachun Zhang
Jiachun Zhang
MZMin Zhang
Min Zhang
ZOZihao Ou
Zihao Ou
YPYongzheng Peng
Yongzheng Peng
Phascolarctobacterium can produce short-chain fatty acids, including acetate and propionate, and can be associated with the metabolic state and mood of the host. The present study investigated the colonization characteristics of Phascolarctobacterium faecium in healthy individuals <1-80 years old in Southern China. A total of 150 fresh fecal samples were collected, and bacterial DNA was isolated from these samples for quantitative polymerase chain reaction analysis. Phascolarctobacterium faecium demonstrated a high colonization rate and abundant colonization in the human gastrointestinal tract. The colonization rate varied between 43.33‑93.33%, and the abundance of Phascolarctobacterium faecium ranged between 3.22‑5.76 log cells g‑1 (1 year old). The permillage of Phascolarctobacterium faecium in total bacteria ranged between 0.004‑1.479. There was presence of Phascolarctobacterium faecium‑like bacteria in younger individuals with a gradual increase in the number of bacteria maintained at a high level with increasing ages (between 1 and 60 years old), but with a decrease in elderly individuals (>60 years old). The results of the present study demonstrated that Phascolarctobacterium faecium is abundantly colonized in the human gastrointestinal tract.

22 April 2020 in Nutrition & Diabetes
Verified
Journal Article
Open access
PDF file
ZOZihao Ou
Zihao Ou
LDLulu Deng
Lulu Deng
ZLZhi Lu
Zhi Lu
FWFeifan Wu
Feifan Wu
WLWanting Liu
Wanting Liu
YPYongzheng Peng
Yongzheng Peng
Objective: Alzheimer’s disease (AD) is a global health problem without effective methods to alleviate the disease progression. Amyloid β-protein (Aβ) is widely accepted as a key biomarker for AD. Metabolic syndromes, including obesity and insulin resistance, are key high risk factors for AD. Akkermansia muciniphila (Akk), the only representative human gut microbe in the genus Verrucomicrobia, can prevent the weight gain caused by a high-fat diet, repair the damaged integrity of the intestinal epithelium barrier, reduce endotoxin levels in blood and improve insulin resistance. The aim of this study is to explore the impact of Akk administration in AD model mice in different diets. Methods: APP/PS1 mice were fed either a normal chow diet or a high-fat diet and were treated with Akk by gavage each day for 6 months. The impacts of Akk on glucose metabolism, intestinal barrier and lipid metabolism in the mouse model of AD were determined. Changes in brain pathology and neuroethology were also analyzed. Results: Akk effectively reduced the fasting blood glucose and serum diamine oxidase levels, and alleviated the reduction of colonic mucus cells in APP/PS1 mice. After treatment with Akk, the APP/PS1 mice showed obviously reduced blood lipid levels, improved hepatic steatosis and scapular brown fat whitening. Moreover, Akk promoted the reduction of Aβ 40–42 levels in the cerebral cortex of APP/PS1 mice, shortened the study time and improved the completion rate in Y-maze tests. Conclusion: Akk effectively improved glucose tolerance, intestine barrier dysfunction and dyslipidemia in AD model mice. Our study results suggested that Akk could delay the pathological changes in the brain and relieve impairment of spatial learning and memory in AD model mice, which provides a new strategy for prevention and treatment of AD.

18 October 2017 in BMC Genomics
Verified
Journal Article
Open access
PDF file
XGXianfeng Guo
Xianfeng Guo
SLShenghui Li
Shenghui Li
JZJiachun Zhang
Jiachun Zhang
FWFeifan Wu
Feifan Wu
XLXiangchun Li
Xiangchun Li
YPYongzheng Peng
Yongzheng Peng
Akkermansia muciniphila is one of the most dominant bacteria that resides on the mucus layer of intestinal tract and plays key role in human health, however, little is known about its genomic content. Herein, we for the first time characterized the genomic architecture of A. muciniphila based on whole-genome sequencing, assembling, and annotating of 39 isolates derived from human and mouse feces. We revealed a flexible open pangenome of A. muciniphila currently consisting of 5644 unique proteins. Phylogenetic analysis identified three species-level A. muciniphila phylogroups exhibiting distinct metabolic and functional features. Based on the comprehensive genome catalogue, we reconstructed 106 newly A. muciniphila metagenome assembled genomes (MAGs) from available metagenomic datasets of human, mouse and pig gut microbiomes, revealing a transcontinental distribution of A. muciniphila phylogroups across mammalian gut microbiotas. Accurate quantitative analysis of A. muciniphila phylogroups in human subjects further demonstrated its strong correlation with body mass index and anti-diabetic drug usage. Furthermore, we found that, during their mammalian gut evolution history, A. muciniphila acquired extra genes, especially antibiotic resistance genes, from symbiotic microbes via recent lateral gene transfer. The genome repertoire of A. muciniphila provided insights into population structure, evolutionary and functional specificity of this significant bacterium.

1 February 2020 in Anaerobe
Verified
Journal Article
Closed access
FWFeifan Wu
Feifan Wu
XGXianfeng Guo
Xianfeng Guo
MZMin Zhang
Min Zhang
ZOZihao Ou
Zihao Ou
DWDan Wu
Dan Wu
YPYongzheng Peng
Yongzheng Peng

11 May 2023 in Journal of Extracellular Vesicles
Verified
Journal Article
Open access
YCYun Chen
Yun Chen
ZOZihao Ou
Zihao Ou
MPMenglan Pang
Menglan Pang
ZTZixin Tao
Zixin Tao
XZXifen Zheng
Xifen Zheng
LHLiping Huang
Liping Huang
Preeclampsia (PE) is a multisystem disorder with high maternal morbidity and mortality rates. Currently, no practical therapeutic approach is available to prevent PE progression, except for early delivery. Gut dysbiosis is associated with PE development. Previous data showed that the abundance of Akkermansia muciniphila (Am) was lower in patients with PE than in normotensive pregnant women. Here, in this study, decreased abundance of Am was observed in a PE mouse model. Also, we found that administration with Am could significantly attenuate systolic blood pressure, promote foetal growth and improve the placental pathology in mice with PE. Moreover, Am‐derived extracellular vesicles (AmEVs) were transferred from the gastrointestinal (GI) tract to the placenta and mitigated pre‐eclamptic symptoms in PE mice. These beneficial effects of AmEVs were mediated by enhanced trophoblast invasion of the spiral artery (SpA) and SpA remodelling through activation of the epidermal growth factor receptor (EGFR)–phosphatidylinositol‐3‐kinase (PI3K)–protein kinase B (AKT) signalling pathway. Collectively, our findings revealed the potential benefit of using AmEVs for PE treatment and highlighted important host–microbiota interactions.

5 December 2023 in Journal of Extracellular Vesicles
Verified
Journal Article
Open access
ZOZihao Ou
Zihao Ou
BSBo Situ
Bo Situ
XHXinyue Huang
Xinyue Huang
YXYicong Xue
Yicong Xue
XHXiaojing He
Xiaojing He
LZLei Zheng
Lei Zheng
Bacterial extracellular vesicles (BEVs) are nano‐size particles secreted by bacteria that carry various bioactive components. These vesicles are thought to provide a new window into the mechanisms by which bacteria affect their hosts, but their fundamental proprieties within human remain poorly understood. Here, we developed a single‐vesicle analytical platform that enabled BEV detection in complex biological samples of host. Using this platform, we found the presence of BEVs in the host circulation and they were mainly derived from gut microbes. We showed that the levels of circulating BEVs in humans significantly increased with aging due to an age‐related increase in intestinal permeability. Significantly different levels of BEVs in blood were also found in patients with colorectal cancer and colitis. Together, our study provides new insights into circulating BEV biology and reveals their potential as a new class of biomarkers.